Navigation Links
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Date:8/5/2008

The most common moderate/severe related adverse events in the once-daily and twice-daily groups respectively were: diarrhea (17 percent versus 15 percent), nausea (seven percent versus five percent), vomiting (three percent versus four percent), and increased triglycerides (two percent in both groups). There was no statistical difference between the groups.

-- At week 48, the overall impact of Kaletra, dosed once-daily or twice-daily, on grade 3-4 lab abnormalities, including cholesterol and triglycerides, the liver enzymes, SGOT/AST, and creatinine clearance was similar.

-- At week 48, there was a statistically significant difference in the increase of total cholesterol between the once-daily and twice-daily group.

About Abbott's Commitment to Fighting HIV/AIDS

HIV/AIDS is a global problem that demands shared commitment and shared responsibility. Abbott is committed to working with governments, multilateral organizations, nongovernmental organizations and patient groups to expand access to HIV treatments around the world. Abbott has also made significant investments in expanding manufacturing capacity to meet the growing demand for HIV treatment in developing countries.

Abbott's lopinavir/ritonavir formulations are among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicines at a price of US$500 per adult patient per year in all African and least developed countries since 2002, making these medicines more affordable than any generic copies.

Abbott and the company's philanthropic foundation, Abbott Fund, have invested more than US$100 million in the fight against HIV/AIDS in Africa and the developing world. Abbott Fund-supported programs have served more than 700,000 children and families. In addition, more than 250,000 patients have been tested through Abbott Fund-supported voluntary counseling and testing programs, with thousands being referred to treatment programs. Abb
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
5. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 3, 2015  VirtualScopics, Inc. (NASDAQ: VSCP ... solutions, announced today, they are collaborating with a ... philanthropic, epidemiology study partnering with the Ministry of ... has teamed up with a cardiac sonographer to ... results will be used to identify children with ...
(Date:9/3/2015)... SEATTLE , Sept. 3, 2015  Omeros Corporation ... filed patent infringement lawsuits against Par Pharmaceutical, Inc. and ... the U.S. District Court for the District of ... District Court for the District of Delaware ... Act for Par,s infringement of three Omeros patents, U.S. ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hs5hvr/investigation ... "Investigation Report on China Tamsulosin Market, 2010-2019" ... with other a1- adrenergic receptor blockers, tamsulosin hydrochloride ... risk of urinary tract infections and therefore is ... in 1993 in Japan , ...
Breaking Medicine Technology:VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4China Tamsulosin Market Investigation Report 2015 2
... Holdings, Inc. (NYSE and SIX: ZMH), a global leader ... in the 2011 Morgan Stanley Global Healthcare Unplugged Conference ... September 13, 2011, at 9:10 a.m. Eastern Time. ... be accessed via Zimmer,s Investor Relations website at ...
... Sept. 1, 2011 Hill-Rom Holdings, Inc., (NYSE: ... management presentation at the Morgan Stanley Global Healthcare Conference ... 8:35 a.m. ET. You are invited to ... at http://ir.hill-rom.com/events.cfm or access it directly at ...
Cached Medicine Technology:Zimmer Holdings to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:9/3/2015)... ... 03, 2015 , ... DriButts, a non-profit organization dedicated to ... Development Group to manufacture a long-lasting reusable diaper for warm weather climates where ... bring 600 DriButts Diapers to rural areas of Haiti during a trip scheduled ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... Scholarship applications are open for spring 2016. Scholarships are awarded two times each ... For The Warriors® is a national nonprofit dedicated to restoring a sense of ...
(Date:9/3/2015)... Columbus, Ohio (PRWEB) , ... September 03, 2015 ... ... Hartley ( http://www.tamarahartley.com ) announces the release of her debut book, “Stop Wasting ... National Read a Book Day (September 6), Hartley’s guide to overcoming life’s obstacles ...
(Date:9/3/2015)... Bellevue, WA (PRWEB) , ... ... ... Center of Washington, a leading provider of comprehensive eating disorder treatment for ... illnesses, announced today that Ileana Calinoiu, MD has joined the medical treatment ...
(Date:9/3/2015)... ... September 03, 2015 , ... As a result ... fully insured employer-sponsored health insurance plans, more employers are moving to a self-funded ... released from the 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s ...
Breaking Medicine News(10 mins):Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... in Favor of Kentucky Oil, BETHEL, Conn., ... a leading provider of nitinol and polymer components ... has received an,unfavorable jury verdict in its disputed ... that Memry breached a,collaboration agreement by providing confidential ...
... YORK (Dec. 20, 2007) -- Using new approaches, an ... Center in New York City has gained a view ... core difficulty in patients with borderline personality disorder -- ... "It,s early days yet, but the work is pinpointing ...
... HeartCentrix(R) ECG Informatics Makes Results from Burdick(R) and, Quinton(R) branded products ... ... 5.0, BOTHELL, Wash. ... ), a leading provider of cardiac,monitoring, defibrillation and rehabilitative products, and ...
... -- Discovery Health Partners with Kashi, America,s Milk Processors and, ... Online and in the ... No Cost to the Participant --, SILVER SPRING, Md., ... to help battle the obesity epidemic,with its biggest and best ...
... study finds that most general surgeons do not discuss ... analysis shows that only one in three patients eligible ... The study is published in the February 1, 2008 ... Cancer Society. , The option of breast reconstruction has ...
... Dec. 20 The Campaign to End,Obesity (the ... 2008 Democratic,and Republican presidential candidates failed to respond ... address the Nation,s obesity epidemic,if elected. Only Senators ... the Campaign,s questionnaire, which was distributed to the,candidates, ...
Cached Medicine News:Health News:Memry Corporation Plans to Appeal Unfavorable Court Result 2Health News:Memry Corporation Plans to Appeal Unfavorable Court Result 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 4Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems' MicroMD(R) EMR 5.0 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems' MicroMD(R) EMR 5.0 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems' MicroMD(R) EMR 5.0 4Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems' MicroMD(R) EMR 5.0 5Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 2Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 3Health News:Reconstruction surgery rarely discussed with breast cancer patients 2Health News:2008 Presidential Hopefuls Fail to Respond to Questions About Obesity in U.S. 2
... and Maximum ACT introducers represent the ... hemostasis introducers in the world. They ... introducers for use in interventional cardiology ... stenting, atherectomy, temporary pacing, endomyocardial biopsies, ...
... hemostasis introducers provide outstanding insertion ... dilator-to-sheath transitions, high kink resistance ... dual layer sheath cannula provides ... works with an extra strong ...
Bx VELOCITY Coronary Stent with HEPACOAT...
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: